Biogen | 8-K: Current report
Biogen | 8-K: Current report
Biogen | 8-K: Biogen reports strong second quarter 2024 results and raises full year 2024 financial guidance; Second quarter 2024 total revenue of $2.5 billion, GAAP diluted EPS of $4.00 and Non-GAAP diluted EPS of $5.28
Biogen | 8-K: Current report
Biogen | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Biogen | DEFA14A: Others
Biogen | DEF 14A: Definitive information statements
Biogen | 8-K: Current report
Biogen | PRE 14A: Preliminary proxy statements relating to merger or acquisition
Biogen | 8-K: Biogen reports fourth quarter and full year 2023 results and expects return to Non-GAAP EPS growth in 2024
Biogen | 8-K: Current report
Biogen | 8-K: Current report
Biogen | 8-K: Biogen reports third quarter 2023 results and updates full year 2023 guidance
Biogen | 8-K/A: Current report (Amendment)
Biogen | 8-K: Current report
Biogen | 8-K: Current report
Biogen | DEFA14A: Others
Biogen | 8-K: Current report
Biogen | DEFA14A: Others
Biogen | 8-K: Current report
No Data
No Data